DPP4 and neoplasm: In line with in vitro findings, sitagliptin treatment (alone or combined with MTX) effectively reduced DPP4 enzymatic activity, inhibited cholesterol biosynthesis and DHCR24 expression, and suppressed tumor growth in JAR/MTX xenograft model.